RxDoctor Payments Data

Katie Espinola, PA

Physician Assistant · New Hyde Park, NYNPI 1457025405

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 37 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$390
  • AbbVie$287
  • Incyte Corporation$165
  • AstraZeneca$125
  • Bristol Myers Squibb$71
  • Stemline Therapeutics Inc.$32
  • plus $53 from 3 others

What the payments were for

  • Food & beverage$86477%
  • Education$25823%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$23,210
Medicare patients
174
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide15$358,728
Lenalidomide19$263,846
ImbruvicaIbrutinib12$205,543
RevlimidLenalidomide11$171,163
CalquenceAcalabrutinib Maleate11$154,119
XareltoRivaroxaban11$14,860
EliquisApixaban16$12,102
Exemestane13$2,363
Anastrozole77$1,039
Letrozole48$953
Hydroxyurea19$406
Dexamethasone14$313
Tamoxifen Citrate13$246
Oxycodone Hcl15$233
Acyclovir15$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$16$358,72815 claims
Bristol Myers SquibbRevlimid$71$171,16311 claims
AstraZenecaCalquence$125$154,11911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →